IRIS to Present At the Canaccord Adams 29th Annual Global Growth Conference August 13, 2009

CHATSWORTH, Calif., Aug. 3, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the Canaccord Adams 29th Annual Global Growth Conference at 11:00 a.m. Eastern time on Thursday, August 13, 2009 at the Intercontinental Hotel in Boston, Mass.

About IRIS International, Inc.

IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,300 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA(r), platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.

CONTACT:  IRIS International, Inc.
          Cesar Garcia, Chairman and Chief Executive Officer
          818-709-1244, x 7123

          The Wall Street Group, Inc.
          Ron Stabiner
          212-888-4848